SCHEMBL3521085

SCHEMBL3521085

O=C(O)c1c(O)c(Cl)cc2nccnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.44
TTR P02766 1/20 0.41
AKR1C2 P52895 2/20 0.38
AKR1C1 Q04828 2/20 0.38
AKR1C4 P17516 1/20 0.38
AKR1C3 P42330 1/20 0.38
DHODH Q02127 10/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HSP90AA1 P07900 2/20 0.38
MAPT P10636 2/20 0.38
OPRK1 P41145 2/20 0.38
HTT P42858 2/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
CYP3A4 P08684 2/20 0.38
ALOX15B O15296 1/20 0.38
NR1I2 O75469 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525718 0.79 EGLN3 (0.44) DPP4DHODHKDM4EMEN1ALDH1A1
SCHEMBL3518770 0.79 EGLN3 (0.61) EGLN3CYP2C19
SCHEMBL3519604 0.79 KDM4E (0.45) TTRAKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL3520296 0.79 EGLN3 (0.37) DPP4AKR1C2AKR1C1DHODHKDM4E
SCHEMBL3567138 0.76 FABP3 (0.42) ALDH1A1HTTLMNAEGLN3
SCHEMBL3567141 0.73 PTPN1 (0.45) EGLN3KDM5A
SCHEMBL6238025 0.72 DPP4 (0.62) DPP4TTRAKR1C2AKR1C1AKR1C4
SCHEMBL3524401 0.72 EGLN3 (0.46) DHODHLMNAEGLN3PDE10A
SCHEMBL19893538 0.71 TTR (0.48) TTRKDM4EALDH1A1MAPTHTT
SCHEMBL3523631 0.71 EGLN3 (0.47) DHODHKDM4EALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 DPP4 2076/4885TTR 4013/4885AKR1C2 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.